Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Novavax' RSV-influenza combination vaccine

Trial Profile

Novavax' RSV-influenza combination vaccine

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 06 Aug 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Respiratory syncytial virus-influenza virus vaccine (Primary)
  • Indications Influenza virus infections; Respiratory syncytial virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Novavax
  • Most Recent Events

    • 06 Aug 2014 According to a Novavax media release, this trial is expected to begin in early 2015.
    • 09 Oct 2013 Data from this combination respiratory syncytial virus-influenza virus vaccine trial are expected to be reported in the fourth quarter of 2014, according to Novavax.
    • 09 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top